• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Commentary

This Tick-Borne Virus Could Be Worse Than Lyme Disease

By
Durland Fish
Durland Fish
Down Arrow Button Icon
By
Durland Fish
Durland Fish
Down Arrow Button Icon
July 3, 2017, 7:00 AM ET

Powassan encephalitis, a disease caused by Powassan virus, could become the next tick-borne epidemic in the U.S. If it does, it could surpass Lyme disease in its impact upon public health. Transmitted by the same tick that causes Lyme disease, Powassan encephalitis is fatal in about 10% of cases, and half of its survivors suffer permanent brain damage. Worse, there is no treatment or vaccine for it.

Since the discovery of the first and fatal case in Powassan, Ontario in 1959, only sporadic reports of Powassan encephalitis have occurred in southern Canada and some of the bordering U.S. states. But within the past 10 years, the number of reported cases has skyrocketed to more than 75 among 12 states, mostly in the densely populated U.S. Northeast. Massachusetts alone has reported 13 cases with three fatalities within the past three years.

Recent field studies in the Northeast have shown that as many as 5% of deer ticks are infected with Powassan virus. Millions of people are bitten by deer ticks each year, accounting for the more than 30,000 cases of Lyme disease and other tick-borne diseases annually reported by the Centers for Disease Control (CDC). But we do not know what happens to all of the people who must be getting bitten by ticks infected with Powassan virus. The cases being reported are likely to be just the tip of an iceberg.

Public health agencies could be doing much more to respond to yet another public health threat from ticks. In the short term, more clinical research is needed to determine the outcome of infection with Powassan virus in people bitten by infected ticks. As with all new diseases, only the most serious cases receive the attention of public health agencies. The full spectrum of illness caused by Powassan virus is poorly understood, especially when combined with the many other tick-borne pathogens that coexist with Powassan virus in ticks.

Additionally, more field studies are needed to determine where ticks infected with Powassan virus occur within the U.S. so that physicians know where to look for human cases and people will know where to take greater precautions against tick bites. In order to do this, health agencies will need more staffing of medical entomologists who know how to collect and identify ticks.

A vaccine to prevent Powassan encephalitis could be made available by testing and approving the vaccine currently used in Europe to prevent a similar disease known as tick-borne encephalitis. These are closely related viruses and the existing vaccine should have efficacy against Powassan. Vaccines against tick-borne diseases have not been successful in the U.S. mostly because of medical liability costs. But the untreatable and much more serious nature of Powassan encephalitis should change the equation.

In the long term, public health agencies need to get serious about addressing the core of the tick-borne disease problem in the U.S., which is how to control ticks in the environment. One would think that after 30 years of epidemic Lyme disease and other new tick-borne diseases, we would have better knowledge of how to manage the increasing population of infected ticks. But basic field studies on ticks has never been a priority at the National Institutes of Health and the CDC has too little funding to support the major research effort that is needed for our academic institutions to solve the tick problem.

Until this happens, we will continue to lose the battle against new tick-borne diseases.

Durland Fish is professor emeritus of epidemiology at the Yale School of Public Health.

About the Author
By Durland Fish
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

TrumpRx
CommentaryPharmaceutical Industry
TrumpRx is here and it helps, though a bit less than advertised
By Jeffrey Sonnenfeld, Stephen Henriques, Ferron Chen, Asuka Koda and Vanessa McLennanFebruary 11, 2026
2 hours ago
saunders
CommentaryLeadership
Bausch + Lomb CEO: Standing still is the new falling behind
By Brent SaundersFebruary 11, 2026
9 hours ago
shumer
CommentaryEntrepreneurship
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
9 hours ago
profusek
CommentaryCorporate Governance
It isn’t partisan politics to admit that stakeholder capitalism went too far, too fast 
By Robert ProfusekFebruary 11, 2026
10 hours ago
CommentaryE-commerce
Agentic commerce will reward the fastest learners, not the biggest retailers
By Simon JamesFebruary 10, 2026
1 day ago
abhas
CommentaryCloud
I’m Cloudera’s chief strategy officer and here’s why your $1 billion AI budget just became obsolete
By Abhas RickyFebruary 10, 2026
1 day ago

Most Popular

placeholder alt text
Economy
America borrowed $43.5 billion a week in the first four months of the fiscal year, with debt interest on track to be over $1 trillion for 2026
By Eleanor PringleFebruary 10, 2026
1 day ago
placeholder alt text
Economy
It turns out that Joe Biden really did crush Americans' dreams for the future. Just look at how the vibe changed 5 years ago
By Jake AngeloFebruary 10, 2026
1 day ago
placeholder alt text
C-Suite
Meet Jody Allen, the billionaire owner of the Seattle Seahawks, who plans to sell the team and donate the proceeds to charity
By Jake AngeloFebruary 9, 2026
2 days ago
placeholder alt text
AI
As billionaires bail, Mark Zuckerberg doubles down on California with $50 million donation
By Sydney LakeFebruary 9, 2026
2 days ago
placeholder alt text
Economy
China might be beginning to back away from U.S. debt as investors get nervous about overexposure to American assets
By Eleanor PringleFebruary 9, 2026
2 days ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
9 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.